News | May 06, 2010

Everolimus Stents Pickup Japanese Market Share

May 6, 2010 – After entered the Japanese drug-eluting stent market earlier this year, Abbott's Xience V and Boston Scientific's Promus stents picked up share from competitors Medtronic and Cordis, according to the market intelligence firm Millennium Research Group (MRG).

In its peak sales month, Xience V was used in more than 50 percent of drug-eluting stent procedures, and averaged a unit share of just less than 40 percent for the first quarter 2010. Meanwhile, Promus captured approximately one-third of Xience V's unit share during the same time period, despite the fact that the devices are identical and were launched simultaneously.

When Boston Scientific acquired Guidant in 2006, it divested Guidant's cardiovascular businesses to Abbott Vascular. However, under the agreement Boston Scientific can sell a restricted quantity of Guidant's drug-eluting stent, marketed under the Promus brand, for a limited time. In Japan, this agreement ends in June 2012.

"Xience V is out-performing Promus almost three to one in Japan," says Bina Mistry, senior analyst at MRG. "Both devices are identical in clinical safety and efficacy and prices do not vary drastically between the brands.”

She said there are two reasons for this trend. First, because most clinical trials studying this device are predominantly using Xience V, this stent is building up better brand recognition, and in some cases, physicians may even be unaware that the Xience V and Promus are the same device. This phenomenon has occurred in other regions around the world. Second, she said Abbott Vascular has a breadth of successful coronary products, including bare-metal stents and angioplasty balloons, and a strong company image in Japan. “Physicians who prefer the Abbott name may adopt Xience V over Promus," Mistry said.

MRG's Japanese Interventional Cardiology Marketrack gathers data from 110 catheterization labs throughout Japan on a monthly basis. Product categories covered include drug-eluting coronary stents, bare-metal coronary stents, percutaneous transluminal coronary angioplasty (PTCA) balloons, guide wires, guiding catheters, diagnostic catheters, embolic protection devices, intravascular ultrasound (IVUS) catheters, introducer sheaths, atherectomy devices, thrombectomy devices, inflation devices, optical coherence tomography (OCT) devices, and vascular closure devices. MRG also gathers data from the United States, Europe, Asia Pacific, Latin America, and the Middle East. Marketrack subscribers receive thousands of data points, including usage (units, average selling prices, and revenues), procedures, competitor shares, and brand-level information.

For more information: www.MRG.net

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init